MedChemExpress LLC (MCE)
  1. Companies
  2. MedChemExpress LLC (MCE)
  3. Products
  4. MedChemExpress - Model BAY 2965501 - ...

MedChemExpressModel BAY 2965501 - 2732902-08-6

SHARE
BAY 2965501 is a potent and selective diacylglycerol kinase zeta (DGKζ) inhibitor. BAY 2965501 induces pERK activation. BAY 2965501 can be used for the research of cancer[1].
Most popular related searches

MCE products for research use only. We do not sell to patients.

BAY 2965501

MCE China:BAY 2965501

Brand:MedChemExpress (MCE)

Cat. No.HY-153343

CAS:2732902-08-6

Purity:99.43%

Storage:Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month

Shipping:Room temperature in continental US; may vary elsewhere.

Description:BAY 2965501 is a potent and selective diacylglycerol kinase zeta (DGKζ) inhibitor. BAY 2965501 induces pERK activation. BAY 2965501 can be used for the research of cancer.

In Vitro:BAY 2965501 increases natural killer cell- and T-cell-mediated tumor cell killing, and enhances IL2-induced natural killer cell activation[2].

In Vivo:BAY-2965501 inhibits tumor growth inhibition in an F9 testicular teratoma model, and the combination of BAY-2965501 with immune checkpoint blockade results in additive or synergistic effects[3].

IC50 & Target:DGKζ[1] In Vitro BAY 2965501 increases natural killer cell- and T-cell-mediated tumor cell killing, and enhances IL2-induced natural killer cell activation[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> BAY 2965501 Related Antibodies

Hot selling product:Estrone sulfate (sodium)  | Rhodamine Phalloidin  | Methylprednisolone  | Fumonisin B1  | NCT-503  | Brusatol  | Sodium dichloroacetate  | Thymidine  | Alirocumab  | VD2-d14

Trending products:Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References:

[1]. Schubert N, et al. Phosphorylated extracellular signal-regulated kinase (pERK) activation in T effector cells as a target engagement biomarker for the DGKζ inhibitor BAY2965501 in clinical trials. Cancer Research, 2023, 83(7_Supplement): 2116-2116.

[2]. Rienk Offringa, et al. 926 BAY 2965501: a highly selective DGK zeta inhibitor for cancer immunotherapy. Regular and Young Investigator Award Abstracts. Immune Cell Types and Biology.

[3]. Schlicher L, et al. Small molecule inhibitors for cancer immunotherapy and associated biomarkers - the current status. Front Immunol. 2023 Oct 31;14:1297175.  [Content Brief]

Brand introduction:
•   MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world;
•   More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas;
•   The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects;
•   Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services;
•   It has a professional experimental center and strict quality control and verification system;
•   Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products;
•   The biological activity of the products has been verified by the experiments of customers in various countries;
•   A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers;
•   Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world;
•   It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。